Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update

Kodiak Sciences Inc. (NASDAQ:KOD) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,540,000 shares, a decrease of 10.5% from the September 15th total of 1,720,000 shares. Approximately 3.2% of the shares of the company are short sold. Based on an average trading volume of 200,200 shares, the days-to-cover ratio is presently 7.7 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $5.00.

Institutional Trading of Kodiak Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in KOD. SG Americas Securities LLC acquired a new position in Kodiak Sciences in the third quarter valued at about $33,000. Meeder Asset Management Inc. acquired a new position in shares of Kodiak Sciences in the 2nd quarter worth approximately $36,000. Sanctuary Advisors LLC purchased a new position in shares of Kodiak Sciences during the 2nd quarter worth approximately $36,000. Headlands Technologies LLC acquired a new stake in Kodiak Sciences in the 1st quarter valued at approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Kodiak Sciences during the first quarter worth $68,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Kodiak Sciences Stock Up 4.2 %

Shares of KOD opened at $3.00 on Thursday. Kodiak Sciences has a 52-week low of $1.37 and a 52-week high of $7.77. The stock has a market cap of $157.61 million, a PE ratio of -0.68 and a beta of 2.34. The firm’s fifty day moving average is $2.61 and its two-hundred day moving average is $2.98.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01. As a group, research analysts anticipate that Kodiak Sciences will post -3.52 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.